BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Li XX, Liang L, Huang LY, Cai SJ. Standard chemotherapy with cetuximab for treatment of colorectal cancer. World J Gastroenterol 2015; 21(22): 7022-7035 [PMID: 26078581 DOI: 10.3748/wjg.v21.i22.7022]
URL: https://www.wjgnet.com/1007-9327/full/v21/i22/7022.htm
Number Citing Articles
1
Bao T. Le, Prithi Raguraman, Tamer R. Kosbar, Susan Fletcher, Steve D. Wilton, Rakesh N. Veedu. Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer TherapeuticsMolecular Therapy - Nucleic Acids 2019; 14: 142 doi: 10.1016/j.omtn.2018.11.007
2
De-Dong Cao, Hui-Lin Xu, Xi-Ming Xu, Wei Ge. The impact of primary tumor location on efficacy of cetuximab in metastatic colorectal cancer patients with different Kras status: a systematic review and meta-analysisOncotarget 2017; 8(32): 53631 doi: 10.18632/oncotarget.19022
3
Septiara Putri, Siti Rizny F. Saldi, Levina Chandra Khoe, Ery Setiawan, Amila Megraini, Benjarin Santatiwongchai, Ryan R. Nugraha, Vetty Y. Permanasari, Mardiati Nadjib, Sudigdo Sastroasmoro, Armansyah Armansyah. Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia settingBMC Cancer 2023; 23(1) doi: 10.1186/s12885-023-11253-y
4
Svetlana Miroshnichenko, Olga Patutina. Enhanced Inhibition of Tumorigenesis Using Combinations of miRNA-Targeted TherapeuticsFrontiers in Pharmacology 2019; 10 doi: 10.3389/fphar.2019.00488
5
Gil Mullin, Michal Sternschuss, Yosef Landman, Aaron Sulkes, Baruch Brenner. Mitomycin C and capecitabine: An additional option as an advanced line therapy in patients with metastatic colorectal cancerWorld Journal of Gastrointestinal Oncology 2023; 15(11): 1913-1924 doi: 10.4251/wjgo.v15.i11.1913
6
Young Kwang Chae, Keerthi Ranganath, Peter S. Hammerman, Christos Vaklavas, Nisha Mohindra, Aparna Kalyan, Maria Matsangou, Ricardo Costa, Benedito Carneiro, Victoria M. Villaflor, Massimo Cristofanilli, Francis J. Giles. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical applicationOncotarget 2017; 8(9): 16052 doi: 10.18632/oncotarget.14109